Endocrinologist, Assistant Professor, University of Toronto, Credit Valley Hospital and St. Michael's Hospital, Department of Medicine, 507-2300 Eglinton Avenue West, Mississauga, Ontario L5M 2V8, Canada.
Expert Opin Investig Drugs. 2009 Sep;18(9):1365-73. doi: 10.1517/13543780903143753.
Clinical practice guidelines from around the world have continued to highlight the importance of glycemic control in the prevention of diabetes complications. Despite the many tools available to achieve these targets, it remains a constant challenge for healthcare providers and patients alike. Rosiglitazone maleate + metformin hydrochloride extend is a new compound that has the advantage of the clinical experience and knowledge about the current version and the added benefit of being a once daily, single pill option. The existing version of rosiglitazone + metformin has been shown to effectively lower hemoglobin A1C, improve insulin sensitivity and minimize weight gain. It is expected that the new compound will also have similar features, with the added benefit of improved patient adherence given its once daily formulation.
来自世界各地的临床实践指南不断强调血糖控制在预防糖尿病并发症方面的重要性。尽管有许多可用于实现这些目标的工具，但对于医疗保健提供者和患者来说，这仍然是一个持续的挑战。马来酸罗格列酮+盐酸二甲双胍缓释片是一种新的化合物，它具有当前版本的临床经验和知识优势，并且每天服用一次，服用一片即可，具有额外的优势。已证明现有版本的罗格列酮+二甲双胍可有效降低血红蛋白 A1C、改善胰岛素敏感性和最小化体重增加。预计新化合物也将具有类似的特点，由于其每天服用一次的配方，患者的依从性也将得到改善。
